| 13.5 0.7 (5.47%) | 07-14 09:32 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.52 | 1-year : | 20.46 |
| Resists | First : | 15 | Second : | 17.52 |
| Pivot price | 12.36  |
|||
| Supports | First : | 11.34 | Second : | 9.09 |
| MAs | MA(5) : | 13.73 |
MA(20) : | 11.84 |
| MA(100) : | 13.51 |
MA(250) : | 12.42 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 74.7 |
D(3) : | 81.8 |
| RSI | RSI(14): 57.2 |
|||
| 52-week | High : | 39.75 | Low : | 6.26 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PMN ] has closed below upper band by 43.0%. Bollinger Bands are 14.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.77 - 14.87 | 14.87 - 14.95 |
| Low: | 12.63 - 12.72 | 12.72 - 12.79 |
| Close: | 12.67 - 12.81 | 12.81 - 12.93 |
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Tue, 14 Jul 2026
ProMIS Neurosciences (PMN) Reports Dose-Dependent Reduction in A - GuruFocus
Tue, 14 Jul 2026
One Dose of PMN310 Reduced Toxic Amyloid Oligomers in Spinal Fluid - Stock Titan
Tue, 14 Jul 2026
ProMIS Neurosciences Reports First Human Evidence of - GlobeNewswire
Fri, 10 Jul 2026
ProMIS Neurosciences Inc. Financial Statements – NASDAQ:PMN - TradingView
Fri, 12 Jun 2026
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Fri, 27 Feb 2026
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 11.8 (%) |
| Held by Institutions | 74.3 (%) |
| Shares Short | 204 (K) |
| Shares Short P.Month | 189 (K) |
| EPS | -18.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63 % |
| Return on Equity (ttm) | -115.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.73 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.69 |
| PEG Ratio | 0 |
| Price to Book value | 1.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|